NCT04085029
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Radiation Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to site outside of the brain
Exclusions:
https://ClinicalTrials.gov/show/NCT04085029